Surrozen, Inc. (SRZN)
Develops antibody drugs that activate tissue repair pathways to treat eye, organ, and nerve diseases.
$19.40-0.02%Healthcare
StockGlow Score
Leaning Bullish
BearishBullish
1 year ago+76.4%
The outlook
SRZN is trading near $19.40 with unanimous Strong Buy analyst coverage. The stock sits well below its 50- and 200-day moving averages, positioning it in the lower half of its 52-week range. Analysts' average price target sits roughly 119% above the current level.
What’s behind the score
Analyst consensusStrong Buy — 1.0 avg of 4 analysts
Price trendBelow its 50- & 200-day averages
52-week range41% of the way from its 52-week low to high
Price targetAvg target +119% vs current price
Analyst price target
~12-month · 4 analysts$42.50average target+119.1% vs now
Now $19.40
Low $40.00High $44.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$225.2M
52-wk high
$35.00
52-wk low
$8.70
50-day avg
$23.94
200-day avg
$22.68
Trailing P/E
—